Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. Case report: We describe a case of a 32-year-old man who started at 18 years with cannabinoids and ketamine, and is currently using N-methyl-D-aspartate (NMDA) antagonists. At age 23, he developed social withdrawal after being assaulted by a stranger, but did not consult psychiatrists until age 26; during this period, he was using internetpurchased methoxetamine and ketamine, and was persecutory, irritable, suspicious, and insomniac and discontinued all received medical prescriptions. He added dextromethorphan to his list of used substances. At age 31, while using phencyclidine, and, for the first time, methoxphenidine, he developed a religious delusion, involving God calling him to reach Him, and the near-death experiences ensured by NMDA antagonists backed his purpose. He received Diagnostic and Statistical Manual of Mental Disorders, 5th Edition diagnosis of multisubstanceinduced psychotic disorder and was hospitalized 8 times, 6 of which after visiting the emergency room due to the development of extreme anguish, verbal and physical aggression, and paranoia. He reportedly used methoxphenidine, methoxyphencyclidine, ethylnorketamine, norketamine, and deschlorketamine, to achieve near-death experiences, and eventually to reach God in heavens.
I
nternet-purchased illicit drug use is becoming increasingly prevalent and a regulatory/legislative and public health problem. Novel psychoactive substance (NPS) use prevalence is currently unknown. The public health threat from their use stems from the poor knowledge of their effects, inadequate human testing, and mislabeling as bath salts, spices, or research chemicals (Hohmann et al., 2014) . Moreover, the uncertain labeling as legal or illegal and their frequent passage from 1 category to another, further adds to the confusion about their use (Wilkins, 2014) .
NPS purchase was shown to occur for about 60% through the internet in a Swedish study (Soussan and Kjellgren, 2016) , but a Dutch study found the internet to represent a means for gathering information about NPS, with friends playing a major role (van Amsterdam et al., 2015) .
Dissociative NPS accounted for about 10% of total NPS use in 1 survey, and methoxetamine, a ketamine-like substance, significantly outnumbered all other NPSs (Soussan and Kjellgren, 2016) .
CASE REPORT
The police brought a 32-year-old man to the emergency room (ER) after he had kidnapped a priest and requested to speak to the Pope, because God prompted him to take the vows. He was compulsorily hospitalized at the psychiatric department with agitation and restricted consciousness. Blood and urine samples were negative for ethanol, benzodiazepines, cannabinoids, cocaine, amphetamine, methadone, opioids, and tricyclic substances. We sent 10 mL serum (kept at À20 8C) to the Pavia Poison Control Center (PPCC), which used gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry to identify the N-methyl-D-aspartate (NMDA) inhibitor methoxphenidine. He reportedly took methoxphenidine to give him the courage to kidnap the priest, and to facilitate his taking vows. We introduced 800 mg/d valproate and 15 mg/d aripiprazole, that the patient told us he would discontinue as soon as he was discharged. During his 6-day hospitalization, he sought to speak to a priest. He reported that he was hearing for some years God's call.
His development was normal and his family history free from psychiatric disorders. As a youngster, he had studied arts and became a successful painter. At age 18, he started using alcohol, cannabinoids, which he reported disliking, and ketamine. At age 20, he intensified drug use, meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria for multisubstance use disorder; meanwhile, he was increasingly withdrawing from social activities. He started working as a member of the administrative staff of his father's employers and organized exhibits of his paintings, but soon left his job, as he developed dysphoria and suspiciousness about colleagues. He sought help at a psychiatric community service and was prescribed 10 mg/d olanzapine. Psychotic symptoms improved, but relapsed upon treatment discontinuation the next month; hence he was hospitalized for 10 days, improved on 10 mg/d olanzapine and 2 mg/d haloperidol, and remained well for about 1 month. He developed insomnia and consulted a neurologist, who abruptly discontinued all antipsychotics and introduced amitriptyline. At about the same time, he started using oral dextromethorphan syrup, initially for medical, and subsequently for recreational purposes. His anxiety increased unbearably along with insomnia; he reported concurrent agitation, fearfulness, appetite loss, and delusional mood. He was hospitalized for 18 days and treated with 1000 mg/d sodium valproate and 20 mg/d aripiprazole, diagnosed with DSM-IV-TR psychosis, not otherwise specified, improved for 1 month, and then discontinued, feeling well and clear of substances. However, 2 months later, he developed paranoia after using online purchased methoxetamine. Upon compulsory rehospitalization, he received again valproate/aripiprazole combination. He was discharged 2 weeks later and went to Northern Italy to visit a substance use specialist, who arranged for monthly sessions.
At age 28, during 1 session, he manifested verbal aggression, irritability, and restlessness, and tried to forcibly obtain dextromethorphan. After being compulsorily hospitalized, he was referred to our service, where he was administered 800 mg/d valproate and 15 mg/d aripiprazole. He was discharged 20 days later with DSM-IV-TR substance-induced psychosis and once again discontinued treatment. Between age 28 to 31, he underwent no hospitalization and alternated periods of living with his parents and no substance use, with periods of staying alone and engaging in online purchase, and use of dextromethorphan, ketamine, and other unspecified drugs and alcohol consumption. At age 31, he returned to our hospital's ER for agitation and extreme anguish. He was discharged with a diagnosis of unspecified acute substance intoxication, but 20 days later, he returned to ER and was sent to our acute psychiatric care unit. After 6 days of 800 mg/d valproate and 15 mg/d aripiprazole, he was discharged; he was no longer hallucinatory and denied delusions.
Twenty-five days later, the patient was rehospitalized for 2 weeks due to violent and megalomanic behavior after substance use he refused to reveal. We immediately obtained biological fluid samples and sent them to the PPCC along with bags his mother had found in his room. Deschlorketamine was found in urine and in some of the bags, and the synthetic cannabinoid, methyl (S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (5F-ADB), in other bags. He said that 5F-ADB was a gift from an internet dealer, but he never used it.
We prescribed 30 mg/d aripiprazole and 5 mg/d clonazepam, and discharged him, but he immediately discontinued and engaged in property damage that led to forcible rehospitalization. On admission, he showed agitation, confusion, cardio-acceleration, marginally higher diastolic blood pressure and body temperature, somewhat elevated lactate, and lower pO 2 . With rehydration and 2000 mg paracetamol, blood chemistry normalized 24 hours later. Despite his oppositional attitude, he provided signed, informed consent for publication of his case. Discharged against medical advice, he returned to community care. As expected, he immediately discontinued medication, but returned to 4-weekly scheduled visits at the community center, where he received support psychotherapy. He was apparently well at last visit, but then never returned. The last news from him (September 2017) were indirect, describing social withdrawal, embedding in family milieu, and poor autonomy. A detailed account of patient's clinical course is provided in Supplemental Digital Content (http://links.lww.com/JAM/A69).
DISCUSSION
Our patient started using NMDA antagonists 14 years ago, along with cannabis and alcohol, but increasingly concentrated on NMDA antagonist use. He never stopped substance use, and the psychosis he developed is apparently associated to the substances used, although cause-effect relations are always hard to demonstrate. He started purchasing drugs on the internet 7 years ago, that is, halfway in his drug use history. Through the internet, the patient was able to purchase and use a long list of drugs, mostly NMDA antagonists (Table 1 ). The unique feature of this patient is that he pursued only NMDA antagonist use with a specific, transcendence-related purpose.
The patient apparently, but not admittedly, ingested methoxetamine in December, 2011; the drug became available by 2010 in UK, and spread to the rest of the world since Chinese laboratories decided to produce it (reported in the study by Maskell et al., 2016) . This drug, like other arylcyclohexamines, is a noncompetitive NMDA antagonist that binds the dizocilpine site with higher affinity than ketamine and lower than phencyclidine (PCP) (Roth et al., 2013) . It is still unclear if and to what extent methoxetamine blocks the dopamine transporter (DAT). Our patient developed delusions and auditory hallucinations while taking this drug (setting, substance purity, and morbidity, may affect presentation), whereas he showed more dissociative symptoms (derealization, absent-mindedness, amnesia) while on ketamine or when taking the newer NPS, methoxphenidine. The latter has been developed to overcome legal restrictions regarding arylcyclohexylamines, and is a diarylethylamine that is a more potent NMDA inhibitor than PCP, while possessing weak antagonist properties for the norepinephrine transporter (NET) and DAT, but negligible affinity for the serotonin transporter (5-HTT) (Wallach et al., 2016) . Clinical picture differences between these 2 NMDA antagonists may depend on their class (Wallach et al., 2016) DAT and/or NET inhibitor (Wallach et al., 2016) Weak s 1 , weaker s 2 ligand (Wallach et al., 2016) 
Strong NMDA receptor uncompetitive antagonist (Iversen, 2012) Moderate 5-HTT antagonist (Iversen, 2012) Strong s 1 receptor agonist (Iversen, 2012) No appreciable affinity for m-opioid receptors or DAT (Iversen, 2012) 
Weaker NMDA receptor uncompetitive antagonist than PCP, but stronger than ketamine (Iversen, 2012) Probable NET inhibitor (Iversen, 2012) Strong to moderate s 1 receptor agonist, but less than 3-MeO-PCP; moderate s 2 receptor ligand (Iversen, 2012) No appreciable affinity for DAT ( Iversen, 2012) 
NMDA receptor antagonist with effects not very dissimilar to ketamine (Iversen, 2012) Other properties not investigated
Ketamine metabolite Strong noncompetitive NMDA receptor antagonist (K i ¼ 1.7 mM for the L-isomer and 13 mM for the D-isomer) (Smith et al., 2009) More potent antagonist than ketamine of a 7 -nicotinic acetylcholine receptors (Paul et al., 2014 ) Deschlorketamine Arylcyclohexylamine (R/S)-2-(2-phenyl)-2-(methylamino)cyclohexanone NMDA receptor antagonist (Frison et al., 2016) Insufficiently investigated on other receptor/transporter systems
Uncompetitive NMDA antagonist NO synthase inhibitor (Mion and Villevieille, 2013) m > k > d-opioid activator (Mion and Villevieille, 2013; Hustveit et al., 1995) Muscarinic antagonist (less potent than NMDA) (Mion and Villevieille, 2013; Hustveit et al., 1995) NET/DAT unaffected by enantiomers and metabolites (Can et al., 2016) (5-HTT inhibitor) (Mion and Villevieille, 2013) s ligand (Hustveit et al., 1995) Weak GABA-mediated Cl À current enhancer (Mion and Villevieille, 2013) (arylcyclohexyl-vs diarylethyl-) and subtle differences in receptor profile. Methoxetamine, methoxphenidine, and 3 and 4-methoxyphencyclidine have been associated with fatalities; their toxicity has been described in various papers (see Supplemental Digital Content, http://links.lww.com/JAM/ A69) and explain much of our patient's symptomatology.
The fact that our patient was a person with polysubstance use adds to clinical picture complexity and does not allow us to attribute individual symptoms to specific drugs. However, his preference for NMDA antagonists prompts us to attribute most of displayed symptoms during his long drug use history to glutamate receptor blockade, interacting with patient's personality characteristics. We know of very few patients so much dedicated to anti-NMDA drug consumption alone.
To face the current increase in NPS use based on internet drug purchasing, repressive measures taken against internet sellers appear to be ineffective, as closing vendor sites results in fast adaptation (Mounteney et al., 2016) , reminiscent of Hercules labor against the Lernean hydra. Public educational policies should focus on correctly informing people about NPS effects.
The current expansion of the NPS market and the trend to multisubstance use render the clinical presentations of persons who use and buy NPS on the internet difficult to recognize and classify. Untoward reactions to drugs or drug combinations may arise any time during a drug use career and may be sometimes life-threatening. Sometimes, NMDA antagonists are used to seek near-death experiences, so people who use them should be warned that sometimes they may get dangerously close. Dextromethorphan Morphinan -3-methoxy-17-methyl-9a, 13a, 14a-morphinan, (þ)-cis-1,3,4,9, 10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, (4bS,8aR,9S)-3-Methoxy-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene
